Medicare Part D spending on diabetes drugs increased 364% from 2019 to 2023, driven by GLP-1 and SGLT-2 inhibitors. Metformin spending decreased by 5%, contrasting with the surge in other diabetes ...
Medicare Part D spending on 10 diabetes drugs reached $35.8 billion in 2023, a 364% increase from 2019 at $7.7 billion, according to a February report from the Office of Inspector General (OIG).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback